Ashley E. Ross, MD, PhD
Ashley E. Ross, MD, PhD

Associate Professor
Departments of Urology, Oncology and Pathology
Johns Hopkins School of Medicine

Cancer Research Building II, Suite 157, Room 152 1550 Orleans Street Baltimore, MD 21287

Appointments: 410-955-6100

Office: (443) 287-7225


Fax: (410)-614-8096


Free Access to abstracts at PubMed


  1. Tretter T*, Ross AE*, Dordai DI, Desiderio S.  Mimicry of pre-B cell receptor signaling by activation of the tyrosine kinase Blk.  J Exp Med.  2003 Dec 15; 198(12):  1863-73. 
  2. *Equal contribution first authorship.

  3. Ross AE, Vuica M, Desiderio S.  Overlapping signals for protein degradation and nuclear localization define a role in intrinsic RAG-2 nuclear uptake in dividing cells.  Mol Cell Biol. 2003 Aug;23(15):5308-19.

  4. Jiang H, Ross AE, Desiderio S.  Cell cycle-dependent accumulation in vivo of transposition-competent complexes between recombination signal ends and full-length RAG proteins.  J Biol Chem.  2004 Feb 27;279(9):  8478-86.
  5. Role:  Project Design, experimental procedures, writing, manuscript approval.

  6. Jiang H, Chang FC, Ross AE, Lee J, Nakayama K, Nakayama K, Desiderio S. Ubiquitylation of RAG-2 by Skp2-SCF links destruction of the V(D)J recombinase to the cell cycle. Mol Cell  2005 Jun 10;18(6):  699-709.
  7. Role:  Experimental support / troubleshooting, data collection, drafting, manuscript approval.

  8. Ross AE, Handa S, Lingeman JE, Matlaga BR.  Kidney stones during pregnancy:  an investigation into stone composition.  Urol Res.  2008 May; 36(2):  99-102.

  9. Loeb S, Epstein JI, Ross AE, Shultz L, Humphreys EB, Jarow JP.  Benign prostate glands at the bladder neck margin in robotic vs open radical prostatectomy.  BJU Int 2010 Mar 25.
  10. Role:  Data collection, manuscript drafting, data analysis

  11. Ross AE, Loeb S, Landis P, Partin AW, Epstein JI, Ketterman A, Feng Z, Carter HB, Walsh PC.  Prostate-specific antigen kinetics during follow-up are an unreliable trigger for intervention in a prostate cancer surveillance program.  J Clin Oncol.  2010 Jun 10;28(17):2810-6.

  12. Bivalacqua TJ, Ross AE, Strong TD, Gebska MA, Musicki B, Champion HC, Burnett AL.  Attenuated RhoA/Rho-Kinase signaling in the penis of transgenic sickle cell mice.  Urology. 2010 Aug: 76(2):510.e7-12.
  13. Role:  Experimental support, analysis, draft review

  14. Emadi A, Ross AE, Cowan KM, Fortenberry YM, Vuica-Ross M.  A chemical genetic screen for modulators of asymmetrical 2,2’-dimeric naphthoquinone cytotoxicity in yeast.  PLoS ONE 2010, May 26;5(5):e10846.
  15. Role:  Experimental support, analysis, draft review

  16. Cilip CM, Ross AE, Jarow J, Fried NM.  Application of an optical clearing agent during noninvasive laser coagulation of the canine vas deferens.  J Biomed Opt. 2010 Jul-Aug; 15(4):04001.
  17. Role:  Experimental support, manuscript drafting.

  18. Ross AE, Emadi A, Marchionni L, Hurley PJ, Simons BW, Schaeffer EM, Vuica-Ross M.  Dimeric napthoquinones, a novel class of compounds with prostate cancer cytotoxicity.  BJU Int.  2010 Dec 22.

  19. Ross AE, Marchionni L, Vuica-Ross M, Cheadle C. Fan J, Berman DM, Schaeffer EM.  Gene expression pathways of high grade localized prostate cancer.  Prostate 2011, Feb 25.

  20. Pierorazio PM, Ross AE, Schaeffer EM, Epstein JI, Han M, Walsh PC, Partin AW.  A contemporary analysis of outcomes of adenocarcinoma of the prostate with seminal vesicle invasion (pT3b) after radical prostatectomy.  J Urol 2011.  May; 185(5):  1691-7.
  21. Role:  Study design, analysis, draft review.

  22. Ross AE, Marchionni L, Phillips TM, Miller RM, Hurley PJ, Simons BW, Salmasi AH, Schaeffer AJ, Gearhart JP, Schaeffer EM.  Molecular effects of genistein on male urethral development.  J. Urol 2011.  May; 185(5):1894-8.
  23. Loeb S, Feng Z, Ross AE, Trock BJ, Humpreys EB, Walsh PC. Can we stop prostate-specific antigen testing 10 years after radical prostatectomy?  J Urol 2011.  Aug; 186(2):  500-5.
  24. Role:  Study design, analysis, draft review.

  25. Pierorazio PM, Ross AE, Han M, Epstein J, Walsh PC, Partin A, Schaeffer EM.  Evolution of the clinical presentation of men undergoing radical prostatectomy for high-risk prostate cancer.  BJUI 2011, Aug 22.
  26. Role:  Study design, analysis, draft review.

  27. Cilip CM, Pierorazio PM, Ross AE, Allaf ME, Fried NM.  High-frequency ultrasound imaging of non-invasive laser coagulation of the canine vas deferens.  Lasers Surg Med.  2011 Sep: 43(8):  838-42.
  28. Role:  Experimental support, manuscript review

  29. Emadi A, Le A, Harwood CJ, Stagliano KW, Kamangar F, Ross AE, Cooper CR, Dang CV, Karp JE, Vuica-Ross M.  Metabolic and electrochemical mechanisms of dimeric naphthoquinones in cytotoxicity in breast cancer cells.  Bioorg Med Chem.  2011 Dec 1:  19(23):  7057-62.
  30. Role:  Experimental Support, manuscript review

  31. Ross AE, Feng Z, Pierorazio PM, Landis P, Walsh PC, Carter HB, Trock BJ, Schaeffer EM.  Effects of treatment with 5-Alpha reductase inhibitors on progression in monitored men with favourable-risk prostate cancer.  BJU Int.  2012 Jan
  32. Pierorazio PM, Ross AE, Lin BM, Epstein JI, Han M, Walsh PC, Partin AW, Pavlovich CP, Schaeffer EM.  Preoperative characteristics of high-Gleason disease predictive of favourable pathological and clinical outcomes at radical prostatectomy.  BJU Int.  2012 Feb28.
  33. Role:  Experimental design, manuscript drafting and review

  34. Huang Z, Hurley PJ, Simons BW, Marchionni L, Berman DM, Ross AE, Schaeffer EM.  Sox9 is required for prostate development and prostate cancer initiation.  Oncotarget 2012 Jul 2.
  35. Role:  Data analysis, manuscript drafting and review

  36. Hurley PJ, Marchionni L, Simons BW, Ross AE, Peskoe SB, Miller RM, Erho N, Vergara IA, Ghadessi M, Huang Z, Gurel B, Park BH, Davicioni E, Jenkins RB, Platz EA, Berman DM, Schaeffer EM.  Secreted protein, acidic and rich in cystein-like 1 (SPARCL1) is down regulated in aggressive prostate cancer and is prognostic for poor clinical outcome.  Proc Natl Acad Sci U S A. 2012 Sep 11;109(37):14977-82. Epub 2012 Aug 27.
  37. Role:  Contribution of specimens / data, experimental design, manuscript review

  38. Simons BW, Hurley PJ, Huang Z, Ross AE, Miller R, Marchionni L, Berman DM, Schaeffer EM.  Wnt signaling through beta-catenin is required for prostate lineage specification.  Dev Biol. 2012 Aug 30.
  39. Role:  Data analysis, manuscript drafting and review

  40. Sundi D, Ross AE, Humphreys E, Han M. Partin AW, Carter HB, Schaeffer EM.  African American men with very low risk prostate cancer exhibit adverse oncologic outcomes after radical prostatectomy.  Is active surveillance still an option?  JCO 2013 Aug 20(24)2991-7.
  41. Role:  Experimental design, data analysis, manuscript review

  42. Pierorazio PM, Gorin MA, Ross AE, Feng Z, Trock BJ, Schaeffer EM, Han M, Epstein JI, Partin AW, Walsh PC, Bivalacqua TJ.  Pathological and oncologic outcomes for men with positive lymph nodes at radical prostatectomy:  The Johns Hopkins Hospital 30-year experience.  Prostate 2013 Sept 9.
  43. Role:  Data analysis, manuscript review

  44. Pierorazio PM, Mullins JK, Ross AE, Hyams ES, Partin AW, Han M, Walsh PC, Schaeffer EM, Pavlovich CP, Allaf ME, Bivalacqua TJ.  Trends in immediate peri-operative morbidity and delay in discharge after open and minimally invasive radical prostatectomy (RP): a 20-year institutional experience.  BJU Int 2013 Jul; 112 (1):45-53.
  45. Role:  Data analysis and experimental design, manuscript review.

  46. Sundi D, Wang VM, Pierorazio PM, Han M, Bivalacqua TJ, Ball MW, Antonarakis ES, Partin AW, Schaeffer EM, Ross AE.  Very high risk localized prostate cancer: definition and outcomes.  PCPD 2014. March 17(1):  57-63.

  47. Ross AE, Feng FY, Chadessi M, Erho N, Crisan A, Buerki C, Sundi D, Mitra AP, Vergara IA, Thompson JS, Triche T, Davicioni E, Bergstralh EJ, Jenkins RB, Karnes J, Schaeffer EM.  A genomic classifier predicting metastatic disease progression in men with biochemical recurrence after prostatectomy.  PCPD 2014.  March 17(1):  64-9.

  48. Sundi D, Kryvenko ON, Carter HB, Ross AE, Epstein JI, Schaeffer ME.  Pathological examination of radical prostatectomies in men with very-low-risk disease at biopsy reveals distinct zonal distribution of cancer in African American men.  J Urol. 2014.  191(1):60-7.
  49. Role:  Data analysis, drafting and review of manuscript

  50. Levy DA, Ross AE, Elshafei A, Krishnan N, Hatem A, Jones JS.  Definition of biochemical success following whole gland cryoablation.  J Urol 2014. May 9.
  51. Role:  Data analysis, drafting and review of manuscript

  52. Faisal FA, Sundi D, Pierorazio PM, Ball MW, Humphreys EB, Han M, Epstein JI, Partin AW, Carter HB, Bivalacqua TJ, Schaeffer EM, Ross AE.  Outcomes of men with an elevated PSA as their sole pre-operative intermediate or high risk feature.  BJU Int 2014.  April 15

  53. Sundi D, Wang V, Pierorazio PM, Han M, Partin AW, Tran PT, Ross AE, Bivalacqua TJ.  Identification of men with the highest risk of early disease recurrence after radical prostatectomy.  Prostate 2014.  May 7.
  54. Role:  Data analysis, drafting and review of manuscript

  55. Sundi D, Cohen JE, Cole AP, Neuman BP, Cooper J, Faisal FA, Ross AE, Schaeffer EM.  Establishment of a new prostate cancer muti-disciplinary clinic:  format and initial experience.  Prostate 2015; 75(2):  191-9.
  56. Role:  Experimental design, data analysis, drafting and review of mansucript

  57. Simons BW, Durham NM, Bruno TC, Grosso JF, Schaeffer AJ, Ross AE, Hurley PJ, Berman DM, Drake CG, Thumbikat P, Schaeffer EM.  A human prostatic bacterial isolate alters the prostate microenvironment and accelerates prostate cancer progression.  J Pathol.  2015; Feb; 235(3):  478-89.
  58. Role:  Data analysis, review of manuscript

  59. Faisal FA, Sundi D, Cooper JL, Humphreys EB, Partin AW, Han M, Ross AE, Schaeffer EM.  Racial disparities in oncologic outcomes after radical prostatectomy:  long-term follow-up.  Uroloy 2014 84(6); 1434-41.

  60. Sundi D, Faisal FA, Trock BJ, Landis PK, Feng Z, Ross AE, Carter HB, Schaeffer EM.  Reclassification rates are higher among African American men than Caucasians on active surveillance.  Urology.  2015 85(1):  155-60.
  61. Role:  Data analysis, review of manuscript

  62. Tomlins SA, Alshalalfa M, Davicioni E, Erho N, Yousefi K, Zhao S, Haddad Z, Den RB, Dicker AP, Trock BJ, DeMarzo AM, Ross AE, Schaeffer EM, Klein EA, Magi-Galluzzi C, Karnes RJ, Jenkins RB, Feng FY. Characterization of 1577 Primary Prostate Cancers Reveals Novel Biological and Clinicopathologic Insights into Molecular Subtypes. Eur Urol. 2015 May 8. [Epub ahead of print].
  63. Role:  Specimen contribution, data analysis, review of manuscript

  64. Ross AE, Yousefi K, Davicioni E, Ghadessi M, Johnson MH, Sundi D, Tosoian JJ, Han M, Humphreys EB, Partin AW, Walsh PC, Trock BJ, Schaeffer EM.  Utility of Risk Models in Decision Making After Radical Prostatectomy:  Lessons from a Natural History Cohort of Intermediate and High Risk Men. Eur Urol. 2015 Apr 25. [Epub ahead of print].

  65. Carvalho FL, Marchionni L, Gupta A, Kummangal BA, Schaeffer EM, Ross AE, Berman DM. HES6 promotes prostate cancer aggressiveness independently of Notch signalling. J Cell Mol Med. 2015 Apr 12. [Epub ahead of print].
  66. Role:  Experimental design, data analysis and interpretation, manuscript review

  67. Zhao SG, Jackson WC, Kothari V, Schipper MJ, Erho N, Evans JR, Speers C, Hamstra DA, Niknafs YS, Nguyen PL, Schaeffer EM, Ross AE, Den RB, Klein EA, Jenkins RB, Davicioni E, Feng FY. High-throughput transcriptomic analysis nominates proteasomal genes as age-specific biomarkers and therapeutic targets in prostate cancer. Prostate Cancer Prostatic Dis. 2015 May 19. [Epub ahead of print].
  68. Role:  Contribution of raw material, data analysis, interpretation, manuscript review

  69. Ross AE, Johnson MH, Yousefi K, Davicioni E, Netto GJ, Marchionni L, Fedor HL, Glavaris S, Choeurng V, Buerki C, Erho N, Lam LL, Humpreys EB, Faraj S, Bezerra, Han M, Partin AW, Trock BJ, Schaeffer EM.  Tissue Based Genomics Augment Post-Prostatectomy Risk Stratification in a Natural History Cohort of Intermediate- and High-Risk Men.  European Urology. Eur Urol 2015 Jun 6.

  70. Hurley PJ, Hughes RM, Simons B, Huang J, Miller RM, Shinder B, Haffner MC, Esopi D, Kinura Y, Jabbari J, Ross AE, Erho N, Vergara IA, Faraj SF, Davicioni E, Netto GJ, Yegnasubramanian S, An S, Schaeffer E.  Androgen Regulated SPARCL1 in the Tumor Microenvironment Inhibits Metastatic Progression.  Cancer Res. 2015 Oct 15; 75(20):  4322-34.
  71. Role:  Contribution of specimens, manuscript review

  72. Yamoah K, Johnson MH, Choeurng V, Faisal FA, Yousefi K, Haddad Z, Ross AE, Alshalafa M, Den R, Lal P, Feldman M, Dicker AP, Klein EA, Davicioni E, Rebbeck TR, Schaeffer EM. Novel Biomarker Signature That May Predict Aggressive Disease in African American Men With Prostate Cancer. J Clin Oncol. 2015 Sep 1;33(25):2789-96. Epub 2015 Jul 20.
  73. Role:  Contribution of specimens, manuscript review and drafting

  74. Hurley PJ, Sundi D, Shinder B, Simons B, Hughes RM, Miller RM, Benzon B, Faraj SF, Netto GJ, Vergara IA, Erho N, Davicioni E, Karnes RJ, Yan G, Ewing CM, Isaacs SD, Berman DM, Rider JR, Jordahl KM, Mucci LA, Huang J, An S, Park BH, Isaacs WB, Marchionni L, Ross AE, Schaeffer E. Germline Variants in Asporin Vary by Race, Modulate the Tumor Microenvironment and are Differentially Associated with Metastatic Prostate Cancer.
  75. Clin Cancer Res. 2015 Oct 7. pii: clincanres.0256.2015.
    Role:  Data analysis, interpretation, experimental design, draft review

  76. Faisal FA, Sundi D, Tosoian JJ, Choeurng V, Alshalalfa M, Ross AE, Klein E, Den R, Dicker A, Erho N, Davicioni E, Lotan TL, Schaeffer EM.Racial Variations in Prostate Cancer Molecular Subtypes and Androgen Receptor Signaling Reflect Anatomic Tumor Location. Eur Urol. 2015 Oct 3
  77. Role:  Data analysis, interpretation, experimental design, draft review

  78. Tay KJ, Polascik TJ, Elshafei A, Cher ML, Given RW, Mouraviev V, Ross AE, Jones JS.  Primary Cryotherapy for High-Grade Clinically Localized Prostate Cancer: Oncologic and Functional Outcomes from the COLD Registry. J Endourol. 2015 Oct 20.
  79. Role:  Design, data analysis, interpretation, draft review

  80. Zhao SG, Evans JR, Kothari V, Sun G, Larm A, Mondine V, Schaeffer EM, Ross AE, Klein EA, Den RB, Dicker AP, Karnes RJ, Erho N, Nguyen PL, Davicioni E, Feng FY.  The landscape of prognostic outlier genes in high-risk prostate cancer.  Clin Cancer Res. 2015 Dec 2.
  81. Role:  Contribution of data, resources, manuscript review

  82. Rowe SP, Macura KJ, Ciarallo A, Mena E, Blackford A, Nadal R, Antonarakis E, Eisenberger M, Carducci M, Ross A, Kantoff P, Holt DP, Dannals RF, Mease RC, Pomper MG, Cho SY.  Comparison of PSMA-based 18F-DCFBC PET/CT to Conventional Imaging Modalities for Detection of Hormone-Sensitive and Castration-Resistant Metastatic Prostate Cancer.  J Nucl Med. 2015 Oct 22.
  83. Role:  Data analysis, manuscript review

  84. Faraj SF, Bezerra SM, Yousefi K, Fedor H, Glavaris S, Han M, Partin AW, Humphreys E, Tosoian J, Johnson MH, Davicioni E, Trock BJ, Schaeffer EM, Ross AE, Netto GJ.  Clinical Validation of the 2005 ISUP Gleason Grading System in a Cohort of Intermediate and High Risk Men Undergoing Radical Prostatectomy.  PLoS One. 2016 Jan 5;11(1).
  85. Role:  Project Inception/Design, Writing, Mentorship, Data Collection

  86. Schwen ZR, Tosoian JJ, Sokoll LJ, Mangold L, Humphreys E, Schaeffer EM, Partin AW, Ross AEProstate Health Index (PHI) Predicts High-stage Pathology in African American Men.  Urology. 2015 Dec 10.

  87. Ross AE, Den RB, Yousefi K, Trock BJ, Tosoian J, Davicioni E, Thompson DJ, Choeurng V, Haddad Z, Tran PT, Trabulsi EJ, Gomella LG, Lallas CD, Abdollah F, Feng FY, Klein EA, Dicker AP, Freedland SJ, Karnes RJ, Schaeffer EM.  Efficacy of post-operative radiation in a prostatectomy cohort adjusted for clinical and genomic risk.  Prostate Cancer Prostatic Dis.  2016.  May 3. 

  88. You S, Knudsen BS, Erho N, Alshalalfa M, Takar M, Al-Deen Ashab H, Davicioni E, Karnes RJ, Klein EA, Den RB, Ross AE, Schaeffer EM, Garraway IP, Kim  J, Freeman MR.  Integrated classification of prostate cancer reveals a novel luminal subtype with poor outcome.  Cancer Res.  2016 Jun 14.

  89. Johnson MH, Ross AE, Alshalalfa M, Erho N, Yousefi K, Glavaris S, Fedor H, Han M, Faraj SF, Bezerra SM, Netto G., Partin AW, Trock BJ, Davicioni E, Schaeffer EM.  SPINK1 define a molecular subtype of prostate cancer in men with more rapid progression in a at-risk natural history radical prostatectomy cohort.  J Urol 2016.  May 26.

Review Articles

  1. Musicki B, Ross AE, Champion HC, Burnett AL, Bivalacqua TJ.  Posttranslational modification of constitutive nitric oxide synthase in the penis.  J Androl 2009 Jul-Aug; 30(4):  352-62.

  2. Ross AE, D'Amico AV, Freedland SJ.  Which, when and why? Rational use of tissue-based molecular testing in localized prostate cancer.  Prostate Cancer Prostatic Dis. 2015 Jun 30.

  3. Mouraviev V, Lee B, Patel V, Albala D, Johansen TE, Partin A, Ross A, Perera RJ.  Clinical prospects of long noncoding RNAs as novel biomarkers and therapeutic targets in prostate cancer.  Prostate Cancer Prostatic Dis. 2015 Oct 27.

  4. Miyahira AK, Lang JM, Den RB, Garraway IP, Lotan TL, Ross AE, Stoyanova T, Cho SY, Simons JW, Pienta KJ, Soule HR. Multidisciplinary intervention of early, lethal metastatic prostate cancer: Report from the 2015 Coffey-Holden Prostate Cancer Academy Meeting.  Prostate. 2015 Oct 19.

  5. Rowe SP, Gorin MA, Allaf ME, Pienta KJ, Tran PT, Pomper MG, Ross AE, Cho SY.  PET imaging of prostate-specific membrane antigen in prostate cancer:  current state of the art and future challenges.  Prostate Cancer Prostatic Dis.  2016 May 3.

  6. Tosoian JJ, Ross AE, Sokoll LJ, Partin AW, Pavlovich CP. Urinary Biomarkers for Prostate Cancer.  Urol Clin North Am. 2016 Feb;43(1):17-38.

  7. Ross AE.  Multigene Testing in Localized Prostate Cancer.  J Natl Compr Canc Netw.  2016 May; 14(5 Supl):  659-62.


Book Chapters

  1. Ross AE, Burnett AL.  Anuria and oliguria.  5-Minute Urology Consult, 2nd Ed. 2009.

  2. Ross AE, Burnett AL.  Balanitis and balanoposthitis.  5-Minute Urology Consult, 2nd Ed.  2009.

  3. Ross AE, Bivalacqua TJ.  Bladder Cancer Superficial.  Handbook of Urology.  2012

  4. Ross AE, Bivalacqua TJ.  Invasive Bladder Cancer/Urinary Diversion.  Handbook of Urology.  2012

  5. Ross AE, Stoianovici D, Allaf ME.  MR-Guided Interventions of the Prostate.  Advances in Image Urologic Surgery.  2014.

  6. Ross AE, Rodriguez R.  Development, Molecular Biology and Physiology of the Prostate, Wein:  Campbell-Walsh Urology 11th Ed. In Press 2015

© The Johns Hopkins University, The Johns Hopkins Hospital, and Johns Hopkins Health System. All rights reserved. Disclaimer
Email: | 600 North Wolfe Street, Baltimore, Maryland 21287

urology second opinion urology second opinion